Par/Three Rivers Ribavirin ANDA Is "Approvable"
This article was originally published in The Pink Sheet Daily
Executive Summary
Launch of the Rebetol generic is "on the near-term horizon," Par CEO Tarriff says. Approval is contingent on resolution of labeling issues.
You may also be interested in...
Three Rivers/Par, Sandoz Ribavirin ANDAs Approved By FDA; Companies Will Share Exclusivity
Three Rivers/Par launch Ribasphere at a 10% discount to Schering-Plough’s Rebetol. The generics are approved for use in combination with interferon alfa-2b for the treatment of hepatitis C.
Three Rivers, Sandoz Ribavirin Generics Approved; Labeling "Carves Out" Use With PEG-Intron
Par launches Three Rivers' Ribasphere at a 10% discount to Schering's Rebetol. FDA awards "shared exclusivity" to Three Rivers and Sandoz. The generics are approved for use in combination with interferon alfa-2b for the treatment of hepatitis C.
Three Rivers/Par, Sandoz Ribavirin ANDAs Approved By FDA; Companies Will Share Exclusivity
Three Rivers/Par launch Ribasphere at a 10% discount to Schering-Plough’s Rebetol. The generics are approved for use in combination with interferon alfa-2b for the treatment of hepatitis C.